Allergy Therapeutics plc AGY.L · Stock Open Allergy Therapeutics plc in new tab
Allergy Therapeutics plc Analysis (AGY.L)
Is Allergy Therapeutics plc a good investment? Allergy Therapeutics plc (AGY.L) is currently trading at 5.70 GBX.
Earnings Schedule: Allergy Therapeutics plc is expected to release its next earnings report on Sept. 30, 2026. The market consensus estimate for Forward EPS is -0.01.
Investor FAQ
Does Allergy Therapeutics plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Allergy Therapeutics plc?
Allergy Therapeutics plc is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Sept. 30, 2026. The company currently has a trailing EPS of -0.01.
Company Profile
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 28, 2023 | 2.17 |
Community Discussion